NASDAQ · Diagnostics & Research · USD
Advanced Biomed Inc. (ADVB) Stock Analysis
Advanced Biomed Inc. (ADVB) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ADVB Key Statistics
As of Oct 21, 2026Trading
- Open
- $3.56
- Previous Close
- $3.80
- Day's Range
- 3.15–3.94
- 52-Week Range
- 3.15–24.23
- Volume
- 25.26K
Valuation
- Market Cap
- $6.21M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 48.67
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −5.00
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$2.78M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 5,231.30%
- Shares Outstanding
- 1.65M
- 1-Year Return
- −61.79%
Dividend and dates
- Avg Volume
- 855.60K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ADVB closed at $3.76, −61.79% over 1 year.
Advanced Biomed Inc. (ADVB) has a market capitalization of $6.21M.
In fiscal 2024, ADVB reported revenue of $0.00.
ADVB Stock Return by Calendar Year
Advanced Biomed Inc. (ADVB) return since Mar 2025: what $10,000 became
- 1 year
- $10,000 $3,821
- −61.79%
- Since Mar 2025
- $10,000 $515
- −94.85%
If you had invested $10,000 in Advanced Biomed Inc. (ADVB) at the close on March 6, 2025, the earliest close on record here, it would have been worth $515 at the close on October 21, 2026: −94.85% in total, −83.86% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −35.62% |
| 2025 (partial year) | −92.00% |
As of October 21, 2026.
ADVB Revenue and Earnings by Fiscal Year
FY ends June| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2024 | $0.00 | −$2.78M | — |
| 2023 | $0.00 | −$3.73M | — |
| 2022 | $0.00 | −$4.03M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2024 | $0.00 | — | −$2.54M | −$2.78M | — |
| 2023 | $0.00 | — | −$3.07M | −$3.73M | — |
| 2022 | $0.00 | — | −$2.37M | −$4.03M | — |
Annual figures as reported, in the company's reporting currency. As of June 30, 2024.
ADVB Valuation vs Diagnostics & Research Median
Median of 45 stocks| Metric | ADVB | Diagnostics & Research median | vs median |
|---|---|---|---|
| P/S ratio | 48.67 | 5.23 | 9.3x the median |
| Profit margin | 5,231.30% | −0.93% | 5,232.2 pts above |
Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Diagnostics & Research Stocks
Thermo Fisher Scientific Inc.
$256.61B
DHRDanaher Corporation
$164.40B
NTRANatera, Inc.
$59.59B
AAgilent Technologies, Inc.
$50.12B
IQVIQVIA Holdings Inc.
$45.53B
WATWaters Corporation
$44.92B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B